🧠 This Week in Neuroscience: MS Genetics Breakthrough, $372.5M CNS Funding, AI for Drug Discovery, and More
Explore the latest developments shaping neuroscience, neurology, and rare CNS disease research. This week’s update spans cutting-edge MS genetic risk research, major investment in precision CNS therapies, AI-powered drug permeability predictions, and diagnostic tools redefining metastatic cancer detection in the brain. Plus, FDA priority review for Hunter syndrome therapy, Canadian approval for a pediatric seizure rescue med, and a compelling awareness film on myasthenia gravis.
📌 What’s Inside This Week’s Update
🧬 MS Australia funds EBV-genetic risk research in multiple sclerosis
💊 BioNxt secures patents for sublingual Cladribine MS therapy
✂️ FDA grants orphan drug status to Duchenne MD gene-editing therapy
🧠 MapLight raises $372.5M for CNS precision drug pipeline
🧪 Plus Therapeutics launches CNSide test with ninety-two percent sensitivity and ninety-five percent specificity
🚀 FDA priority review for Denali’s Hunter syndrome brain-penetrant therapy
🤖 Lantern Pharma launches AI tool with ninety-four percent accuracy in BBB permeability prediction
🎥 Alexion premieres Rare Connections myasthenia gravis awareness film
🇨🇦 Health Canada approves Buccolam® pediatric seizure rescue med
⚡ Cassava reports positive preclinical data for simufilam in TSC-related epilepsy
From regulatory wins to AI-driven drug discovery, this week’s roundup spotlights the innovations advancing neuroscience care and research.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and neurodegenerative breakthroughs
#Neuroscience #MultipleSclerosis #GeneTherapy #HunterSyndrome #MyastheniaGravis #AIinHealthcare #EpilepsyResearch #RareDiseases #NeuroUpdates #LucidQuest #ClinicalTrials #FDAupdates #BiotechNews #HealthcareInnovation